A Q&A with Dr. Régine Sitruk-Ware
December 17, 2018
Clinical research in contraceptive care has led to several new treatment options in recent years, but with many needs still unaddressed, researchers continue to seek alternative solutions. Dr. Régine Sitruk-Ware of the Population Council’s Center for Biomedical Research, recently named one of the 50 most influential people in health care in 2018 by TIME for her innovative work in female and male contraception, shared insights on how contraceptive care is evolving.
NAMS 2018: We Can’t Ignore Health Conditions Affecting Half the World’s Population for Half of Their Adult Lives
The North American Menopause Society (NAMS) will hold its 2018 Annual Meeting October 3-6 in San Diego, California. The medical community recognizes the NAMS Annual Meeting as a significant event, and yet it is easy to underestimate the meeting’s full importance.
Think about it. Menopause profoundly affects the health and quality of life of about half of the world’s population for about half of their adult lives. Average female life expectancy in the United States and […]
World Contraception Day is an annual campaign on September 26, supported by 17 nongovernmental organizations (NGOs), “around a vision where every pregnancy is wanted.” In the words of the World Health Organization, World Contraception Day’s mission is “to improve awareness of all contraceptive methods available and enable young people to make informed choices on their sexual and reproductive health.”
Health Decisions considers World Contraception Day an occasion to celebrate the availability of a wide range of contraceptive options while also recognizing that there is […]
The American Sexual Health Association is observing September as Sexual Health Month, in keeping with the World Association for Sexual Health designation of World Sexual Health Day. Sexually transmitted infections (STIs) are by far the most widespread sexual health conditions affecting both women and men. The Centers for Disease Control estimates that there are approximately 20 million new cases of STIs in the United States annually. STIs can pose serious health issues, especially for women, […]
FDA approval of gonadotropin-releasing hormone (GnRH) antagonist elagolix as an oral agent for management of moderate-to-severe pain associated with endometriosis provides an important treatment option for a condition that compromises quality of life for approximately 10% of women of reproductive age. Types of pain associated with endometriosis include painful periods, painful ovulation, pain during or after sexual intercourse and chronic pelvic pain.
Clinical studies that provided a basis for FDA approval demonstrated that three out of four women given 200 mg of elagolix twice a […]
Health Decisions’ CEO Patrick Phillips Supports the #NextGenContraception Campaign
Health Decisions is a women’s health specialty CRO with extraordinary experience and capabilities in contraceptive research. For more than 20 years, Health Decisions has served as the Coordinating Center for the Contraceptive Clinical Trials Network of the National Institute of Child Health and Human Development (NICHD), a unit of the National Institutes of Health. In addition, Health Decisions has conducted many contraceptive […]
Health Decisions supports the recognition of July as Fibroid Awareness Month. Health Decisions’ Chief Medical Officer Andrea S. Lukes, MD, MHSc, FACOG, is a practicing OB/GYN and an active Principal Investigator with experience in uterine fibroid clinical trials. Dr. Lukes offers this blog post in support of fibroid awareness and clinical development of new fibroid therapeutics and diagnostics.
Fibroids are benign tumors of muscle within the uterus. The cumulative incidence by the age of 50 is […]
Development of a noninvasive diagnostic for endometriosis has long been a priority for researchers. For example, a workshop report from the 2011 World Congress of Endometriosis entitled Defining Future Directions for Endometriosis Research noted both the need for a noninvasive diagnostic and the challenge:
- A noninvasive test for the reliable diagnosis of endometriosis, and in particular early endometriosis, remains a priority. Specificity and sensitivity of any diagnostic test are key issues, with many patients having comorbidities, such as adenomyosis, irritable bowel syndrome, and […]
The Health Decisions team at DIA 2018 left with the impression that the biopharma industry values relationships with patient advocacy groups but use of such groups in study planning and protocol development remains the exception rather than the rule. Health Decisions’ Chief Medical Officer Andrea Lukes, MD, MHSc, FACOG, chaired a DIA forum entitled “From Patients and Advocacy Groups to Operations and Beyond: Obtaining and Incorporating Input from Stakeholders in Protocol Design.” Clint Dart, Health Decisions’ Senior Director, Biostatistics and Programming, participated along with […]
Progress in male contraception, including male hormonal contraception, has captured the attention of mainstream media, as demonstrated by an article in the June 18 issue of Time Magazine, “This Man Wants to Be on Birth Control: Inside the race to develop a better male contraceptive.” (Subscription required.) Author Alexandra Sifferlin has provided an excellent overview of the field of male contraception as she did in an April 26 online piece, “Are We Finally Ready for the Male Pill?”
The print article […]